New Delhi, May 10 (IANS) An international team of researchers found that a cholesterol-lowering drug may offer a more effective and convenient way to protect people at high risk of heart attack and stroke.
The study led by researchers at Monash University in Australia tested a once-daily oral medication called Obicetrapib and found it significantly lowered both LDL or bad cholesterol and lipoprotein(a), [Lp(a)] — two key contributors to cardiovascular disease.
The findings marked an important step forward for patients who have struggled to reach their cholesterol targets with current therapies, said study lead Professor Stephen Nicholls, Director of Monash University’s Victorian Heart Institute.
“We know that many people at high risk of heart attack or stroke don’t get their cholesterol levels low enough, even on the best available treatments,” Nicholls said.
“Obicetrapib offers a promising new option-not only did it lower LDL cholesterol by over 30 per cent, but we also saw a reduction in Lp(a), which is much harder to treat and has been linked to increased heart disease risk,” he added.
LDL cholesterol, often referred to as “bad cholesterol,” builds up in blood vessels and increases the risk of heart attack and stroke.
Lipoprotein(a), or Lp(a), is a lesser-known but inherited risk factor that can also accelerate artery damage — and unlike LDL, there are currently no widely approved treatments to lower it.
The trial, published in the New England Journal of Medicine, included more than 2,500 participants with established heart disease or genetic high cholesterol who were given either Obicetrapib or a placebo, in addition to their regular cholesterol medications.
After 12 weeks, those on Obicetrapib had dropped their LDL cholesterol by 32.6 per cent and Lp(a) by 33.5 per cent on average — many achieved guideline-recommended targets for the first time.
Obicetrapib was also well tolerated, with a safety profile similar to earlier trials.
“This could be a valuable tool in the fight against heart disease,” Professor Nicholls said. “It’s convenient, it’s effective, and it may help close the gap for patients who’ve run out of options.”
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
